Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Repotrectinib by Bristol-Myers Squibb for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to...
Repotrectinib by Bristol-Myers Squibb for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Carcinoma. According to...
Repotrectinib by Bristol-Myers Squibb for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According...
Repotrectinib by Bristol-Myers Squibb for Central Nervous System (CNS) Tumor: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Central Nervous System (CNS) Tumor. According...
Repotrectinib by Bristol-Myers Squibb for Renal Cell Carcinoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Repotrectinib by Bristol-Myers Squibb for Angiosarcoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Repotrectinib by Bristol-Myers Squibb for Soft Tissue Sarcoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Repotrectinib by Bristol-Myers Squibb for Uterine Cancer: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
Repotrectinib by Bristol-Myers Squibb for Head And Neck Cancer: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Head And Neck Cancer. According to...
Repotrectinib by Bristol-Myers Squibb for Liver Cancer: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Liver Cancer. According to GlobalData, Phase...
Repotrectinib by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Repotrectinib by Bristol-Myers Squibb for Melanoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Melanoma. According to GlobalData, Phase II...